Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Diagnostic Tests Evaluated for Human Plasmodium knowlesi

By LabMedica International staff writers
Posted on 27 Mar 2014
Rapid diagnostic tests (RDTs) have been evaluated for the diagnosis of Plasmodium knowlesi, a malaria parasite of Southeast Asian macaques, Macaca fascicularis that infects humans and can cause fatal malaria. More...


Until recently only four types of Plasmodium (P. falciparum, P. vivax, P. malariae, and P. ovale) were known to cause malaria in humans, however, a fifth species, P. knowlesi, has been identified as a cause of human malaria in almost all countries in Southeast Asia. P. knowlesi is difficult to diagnose by microscopy because of morphological similarity to P. malariae.

Scientists at the Universiti Malaysia Sarawak, (Malaysia) and their international colleagues diagnosed by microscopy 40 malaria patients, 28 P. knowlesi, 10 P. vivax, and 2 P. falciparum. Patient blood samples were used to determine parasitaemia by microscopy, confirm the Plasmodium species present by polymerase chain reaction (PCR) and evaluate three RDTs using frozen blood samples from 41 P. knowlesi malaria patients.

A large number of RDTs are available for malaria diagnosis, including the three used in this study: OptiMAL-IT (DiaMed; Mississauga, ON, Canada), BinaxNOW Malaria (Alere; Waltham, MA, USA), and Paramax-3 malaria Pf/Pv/Pan (Zephyr Biomedical Systems; Goa, India). The sensitivity of each RDT was calculated with nested PCR results as the reference standard.

OptiMAL-IT was the most sensitive RDT, with a sensitivity of 71% (20/28) for fresh and 73% (30/41) for frozen P. knowlesi samples. However, the test was not specific and P. knowlesi samples cross-reacted with the P. falciparum LDH test reagent in 18 of the 20 fresh samples identified. BinaxNOW Malaria correctly detected non-P. falciparum malaria in P. knowlesi samples but was the least sensitive, detecting only 29% (8/28) of fresh and 24% (10/41) of frozen samples. The Paramax-3 RDT tested positive for P. vivax with PCR-confirmed P. knowlesi samples with sensitivities of 40% (10/25) with fresh and 32% (13/41) with frozen samples. All RDTs correctly identified P. falciparum- and P. vivax-positive controls with parasitaemias above 2,000 parasites/μL blood.

The authors concluded that the sensitivity of detection of P. knowlesi by the three RDTs evaluated is low compared with microscopy. Cross-reactivity is common between P. knowlesi-infected blood and both the P. falciparum-detecting antibody used in the OptiMAL-IT test and the P. vivax-detecting antibody used in the Paramax-3 test. Since not all species of malaria warrant the same level of medical care, misidentification can result in mismanagement, especially when the potentially severe knowlesi malaria is misdiagnosed as vivax malaria. The study was published on February 18, 2014, in the Malaria Journal.

Related Links:

Universiti Malaysia Sarawak
DiaMed
Alere



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.